(Total Views: 653)
Posted On: 04/23/2021 9:13:24 PM
Post# of 151513
“If the US doesn't want to be a customer, so be it.”
Moving CD16 overseas has nothing to do with the U.S. not wanting to be a customer. That’s a misnomer and incorrect as leronlimab is absolutely needed.
Moving CD16 overseas has everything to do with the success of CD16. SOC in India and Brazil is no doubt lower than the U.S., which means a higher mortality rate in the placebo arm. Therefore, leronlimab will no doubt show success vs SOC in these countries. That’s why the trial is going overseas.
Moving CD16 overseas has nothing to do with the U.S. not wanting to be a customer. That’s a misnomer and incorrect as leronlimab is absolutely needed.
Moving CD16 overseas has everything to do with the success of CD16. SOC in India and Brazil is no doubt lower than the U.S., which means a higher mortality rate in the placebo arm. Therefore, leronlimab will no doubt show success vs SOC in these countries. That’s why the trial is going overseas.
(9)
(0)Scroll down for more posts ▼
